OPTILENT

Welcome to the Brand page for “OPTILENT”, which is offered here for Pharmaceutical preparations for the treatment of orphan diseases, inherited disorders of the immune system, inherited metabolic disorders, inherited blood disorders, inherited neuro-degenerative disorders; chemical preparations for pharmaceutical or medical purposes for use in gene therapy for the treatment of orphan diseases, inherited disorders of the immune system, inherited metabolic disorders, inherited blood disorders, inherited neuro-degenerative disorders; medicinal preparations for the treatment of orphan diseases, inherited disorders of the immune system, inherited metabolic disorders, inherited blood disorders, inherited neuro-degenerative disorders;medical services; information, advisory and consulting services in relation to the aforesaid;scientific research and development services in the medical and pharmaceutical fields; product research and development services in the medical and pharmaceutical fields; information, advisory and consulting services in relation to the aforesaid;.

Its status is currently believed to be active. Its class is unavailable. “OPTILENT” is believed to be currently owned by “Orchard Therapeutics (Europe) Limited”.